U.S. Telecom Services and Carriers Stock News

Neogen (NEOG) is back in focus after quarterly results topped market expectations and management lifted full year revenue guidance to US$845 million to US$855 million, alongside a higher adjusted EBITDA outlook. See our latest analysis for Neogen. At a share price of US$9.62, Neogen has seen a sharp shift in sentiment, with a 37.43% 7 day share price return and 61.68% 90 day share price return following its beat and raise quarter and new senior commercial hires, even though the 1 year total...

Hillman Solutions (HLMN) has caught investor attention after recent share price moves, with the stock last closing at US$9.82. That has many holders checking how its recent returns line up with its fundamentals. See our latest analysis for Hillman Solutions. The recent 7 day share price return of 12.74% and 30 day share price return of 6.28% suggest positive momentum building around Hillman Solutions, while the 1 year total shareholder return of 5.71% points to a more modest longer term...

If you are wondering whether Netflix is still a good deal at today's price, this article will walk through what that current market value really reflects. Over shorter periods the stock has been choppy, with a 1.7% decline over the last week and a 6.0% decline over the last month, while the 1 year return sits at 6.8% and the 3 year and 5 year returns are 168.8% and 79.6% respectively. Those moves have kept Netflix in the spotlight as investors reassess what they are willing to pay for...

Axsome Therapeutics recently received formal pre-NDA meeting minutes from the FDA confirming that its existing data package is sufficient to support an NDA submission for AXS-12 to treat cataplexy in narcolepsy, with Orphan Drug Designation potentially enabling seven years of U.S. marketing exclusivity and waiver of FDA user fees if approved. This regulatory progress, combined with Axsome’s broader late-stage neuroscience pipeline targeting serious CNS conditions affecting over 150 million...

In early January 2026, Trinity Industries, Inc. raised its full-year 2025 earnings guidance, lifting expected earnings per share to a range of $3.05 to $3.20 after incorporating a projected $1.50 EPS impact. This upward revision signals management’s increased confidence in Trinity’s earnings power, a key consideration for investors assessing the company’s evolving risk–reward profile. Next, we’ll examine how Trinity’s higher 2025 earnings guidance interacts with earlier assumptions about its...

If you are wondering whether AeroVironment at US$364.99 is priced for perfection or still has room on the table, you are not alone. The stock has moved sharply, with returns of 42.5% over 7 days, 52.7% over 30 days, 42.5% year to date, 121.2% over 1 year and 313.3% over 3 years. This can change how investors think about both upside and risk. Recent coverage around AeroVironment has highlighted its role in capital goods and its exposure to defense related solutions, which often draws...

Valens Semiconductor (VLN) is back on investor radar after securing a fourth MIPI A PHY design win in China and launching a production ready A PHY enabled e mirror with Sakae Riken Kogyo. See our latest analysis for Valens Semiconductor. The recent A PHY design wins and e mirror launch sit against a sharp short term rebound, with a 30 day share price return of 55.97% and year to date share price return of 58.97%. This contrasts with a 1 year total shareholder return decline of 19.48% and a 3...

TFS Financial (TFSL) has drawn fresh attention after its share price moved above its 200 day moving average, coinciding with renewed focus on Wall Street rating upgrades and its recently paid quarterly dividend. See our latest analysis for TFS Financial. At the current share price of $13.91, TFS Financial has been building momentum, with a 7 day share price return of 2.5% and a 90 day share price return of 5.1%, while its 1 year total shareholder return of 24.9% highlights how income from...

Why Sun Communities Is Back on Investors’ Radar Sun Communities (SUI) is back in focus after releasing full year results showing revenue of about US$3.24b alongside a net loss of US$345.4m, prompting a closer look at its fundamentals and recent share price performance. See our latest analysis for Sun Communities. The recent full year figures and net loss have landed against a period of rebuilding momentum, with the 1 year total shareholder return of 11.61% outpacing the more muted 3 year...

Harley-Davidson (HOG) recently reported quarterly results, with revenue up 16.5% year on year and earnings ahead of Wall Street estimates. Despite this, the stock has fallen about 23% since the release. See our latest analysis for Harley-Davidson. That post earnings drop comes after a weaker patch for the shares, with a 90 day share price return of 18.42% and a 1 year total shareholder return of 20.71%, pointing to fading momentum despite the recent 7 day share price gain of 3.83% and year to...

PBF Energy recently drew attention after Piper Sandler upgraded the refiner to Overweight, highlighting its ability to handle Venezuelan heavy sour crude and the planned full restart of the Martinez refinery by March 2026. An interesting angle is how access to Venezuelan barrels could interact with PBF’s complex refining setup, potentially affecting margins differently across its coastal markets. We’ll now examine how Piper Sandler’s upgrade, centered on Venezuelan crude import potential,...

Institutional buying and shareholder returns draw fresh attention Summit Street Capital Management’s decision to add 81,170 shares of Core Natural Resources (CNR) in the third quarter, along with robust quarterly revenue, profitability and free cash flow returned via repurchases and dividends, is now in focus for investors. See our latest analysis for Core Natural Resources. That institutional buying interest comes as Core Natural Resources’ share price has climbed to $96.38, with a 1 month...

NewAmsterdam Pharma recently outlined its late-stage plans for obicetrapib, including an expected EMA approval decision in the second half of 2026, first-patient dosing in the RUBENS Phase 3 metabolic syndrome trial, continued progress in the PREVAIL cardiovascular outcomes study, and preparations for an Alzheimer’s disease trial based on earlier biomarker data. These updates give investors clearer visibility into NewAmsterdam’s pipeline evolution across cardiometabolic and neurological...

LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for presbyopia, across multiple Middle East markets including the UAE, Saudi Arabia and Qatar. The deal builds on VIZZ’s early U.S. launch, where the product generated about US$1.6 million in Q4 2025 revenue from over 20,000 prescriptions and broad uptake by eye care professionals. We’ll explore how early...

In recent months, Flex reported fiscal second-quarter 2026 results that exceeded analyst expectations and its CFO Kevin Krumm sold US$1.31 million of shares to cover tax obligations tied to vesting restricted share units. A parallel milestone was Flex’s JetCool-led liquid cooling deployment at Equinix’s Co-Innovation Facility in Virginia, highlighting energy- and water-efficient solutions tailored to high-density, AI-focused data centers. We’ll now examine how Flex’s JetCool liquid cooling...

In recent days, Meta Platforms announced a series of long-term agreements with Vistra, Oklo and TerraPower to secure about 6.6 gigawatts of nuclear power by 2035 for its U.S. data centers, aiming to supply the massive, always-on electricity demand of its expanding AI infrastructure with low-carbon energy. By effectively becoming one of the largest corporate buyers of nuclear power in U.S. history, Meta is tying its AI growth ambitions directly to advanced, carbon-free baseload generation,...

In 2025, Ubiquiti reported strong business recovery and June-quarter growth, paid down a substantial debt load, reinstated its share repurchase program, and raised its dividend by one-third. With founder and CEO Robert Pera controlling about 93% of the shares, renewed buybacks could further shrink the already limited public float. Next, we’ll explore how Ubiquiti’s debt reduction and renewed capital returns program shape the company’s evolving investment narrative. We've found 12 US stocks...

Why the Visa Direct collaboration matters for Deluxe Deluxe (DLX) is in focus after announcing a collaboration with Visa to integrate Visa Direct into its payments platform, introducing dlxFastFunds as a near real time funding option for business clients. The new service is aimed at helping companies shorten typical settlement delays, with the goal of improving day to day cash flow management for needs such as inventory, payroll, or reinvestment decisions. See our latest analysis for...

Figs Inc. has recently expanded its physical retail footprint by opening “Community Hubs” near hospitals, medical universities, and clinics, creating dedicated spaces that combine healthcare apparel retail with community-oriented services for medical professionals. By offering events, personalization stations, and wellness programming inside these Community Hubs, FIGS is deepening its relationship with core healthcare customers and embedding the brand more directly into their daily...

KLA (KLAC) is back in focus after a cluster of analyst upgrades and a fresh Overweight call from Cantor Fitzgerald, paired with the launch of a new AI focused R&D hub in Chennai. See our latest analysis for KLA. The cluster of upgrades appears to be feeding into strong price momentum, with a 1 day share price return of 5.69% and a 30 day share price return of 17.26%. The 1 year total shareholder return of 106.71% and 5 year total shareholder return of 385.82% point to a story that has been...

Framing LegalZoom.com after recent performance LegalZoom.com (LZ) has attracted fresh attention after a period in which its shares showed positive total returns over the past year and past 3 months, prompting investors to reassess how its fundamentals line up. The company reports annual revenue of US$727.483m and net income of US$22.224m, with revenue growth at 6.61% and net income growth at 47.37%. These figures give investors more concrete data to work with. See our latest analysis for...

In recent weeks, Apple Hospitality REIT has attracted fresh attention as Barclays and Cantor Fitzgerald both initiated and reaffirmed positive coverage, while insiders, including the CEO, increased share purchases and the company acquired the Motto by Hilton Nashville Downtown for US$98.2 million. This combination of upbeat analyst commentary, insider buying and portfolio expansion is sharpening investor focus on how Apple Hospitality’s hotel assets might perform against longer-term...

Veris Residential (VRE) is back in focus after fresh commentary on its ongoing portfolio optimization, including non core asset sales and efforts to reinforce its balance sheet, alongside modest upward earnings estimate revisions for 2025 and 2026. See our latest analysis for Veris Residential. Despite the focus on non core asset sales and balance sheet repair, Veris Residential’s share price return has been relatively muted. The stock has shown a 90 day gain of 1.44% and a slightly negative...

If you are wondering whether Intellia Therapeutics at around US$10.38 is a bargain or a value trap, you are not alone in asking what the current price really reflects. The stock has moved recently, with returns of 12.7% over the last 7 days, 15.1% over the last 30 days and 12.7% year to date, while the 1 year return is 1.8% and the 3 and 5 year returns are 72.4% and 87.3% declines respectively. Recent company specific news helps frame these moves for investors following Intellia Therapeutics...